Roche to Establish Registries to Monitor Health of HIV-Positive People Exposed to Recalled Antiretroviral Viracept
June 25, 2007
Roche on Thursday said that it plans to establish patient registries to monitor the health of HIV-positive people who were taking the company's recently recalled antiretroviral drug Viracept, the Press Association reports (Moynihan, Press Association, 6/21).
The company said it is establishing the patient registries for HIV-positive people exposed to elevated levels of EMS, as well as pregnant women and all children who have ever been exposed to the drug, including those exposed in utero. Roche "take[s] the welfare of patients extremely seriously," Burns said, adding, "With the knowledge we have to date, we consider the risk to patients to be low; however, we want to be sure patients can be followed, and these registries will allow us to do just that" (Press Association, 6/21).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.